<DOC>
<DOCNO>EP-0635505</DOCNO> 
<TEXT>
<INVENTION-TITLE>
4-Aryloxy- and 4-arylthiopiperidine derivatives
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2518	A61K314523	C07D26300	A61K314465	C07D26320	A61P2524	C07D41300	C07D21154	C07D21100	A61K314523	A61P2526	A61P912	A61P2504	A61K31445	C07D41306	A61P900	A61P2522	A61K314465	A61P2500	A61K31445	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	C07D	A61K	C07D	A61P	C07D	C07D	C07D	A61K	A61P	A61P	A61P	A61K	C07D	A61P	A61P	A61K	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61K31	C07D263	A61K31	C07D263	A61P25	C07D413	C07D211	C07D211	A61K31	A61P25	A61P9	A61P25	A61K31	C07D413	A61P9	A61P25	A61K31	A61P25	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel 4-aryloxy- or 4-arylthiopiperidine derivatives of the formula I   
<
IMAGE
>
  in which   R
<
1
>
 and R
<
2
>
 in each case independently of one another are phenyl radicals which are unsubstituted or substituted one or two times by A, OH, OA, aryloxy having 6-10 C atoms, aralkyloxy having 7-11 C atoms, -O-(CH2)n-O-, Hal, CF3, NO2, NH2, NHA, NA2, NHAc, NAAc, NHSO2A and/or NASO2A,   X is O, S, SO or SO2,   m is 1, 2 or 3,   n is 1 or 2,   A is an alkyl radical having 1-6 C atoms,   Hal is F, Cl, Br or I  and Ac is alkanoyl having 1-8 C atoms, aralkanoyl having 1-10 C atoms or aroyl having 7-11 C atoms, and their physiologically acceptable salts, have an action affecting the central nervous system, in particular neuroleptic action, without a noticeable cataleptic action occurring.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
4-Aryloxy- or 4-arylthiopiperidine derivatives of 
the formula I 


 
in which 


R
1
 and R
2
are each, independently of one another, phenyl 
radicals which are unsubstituted or mono- or 

disubstituted by A, OH, OA, aryloxy with 6-10 
C atoms, aralkyloxy with 7-11 C atoms, -O- 

(CH
2
)
n
-O-, Hal, CF
3
, NO
2
, NH
2
, NHA, NA
2
, NHAc, 
NAAc, NHSO
2
A and/or NASO
2
A, 
X
is O, S, SO or SO
2
, 
m
is 1, 2 or 3, 
n
is 1 or 2, 
A
is an alkyl radical with 1-6 C atoms, 
Hal
is F, Cl, Br or I 
 
and 


Ac
is alkanoyl with 1-8 C atoms, aralkanoyl with 
1-10 C atoms or aroyl with 7-11 C atoms, 
 
and the physiologically acceptable salts thereof. 
An enantiomer of a compound of the formula I 
accordinq to Claim 1. 
(a) 3-p-chlorophenyl-5-[(4-p-acetamidophenoxy-piperidino)methyl]-2-oxazolidinone; 
(b) 3-p-hydroxyphenyl-5-[(4-p-acetamidophenoxy-piperidino)methyl]-2-oxazolidinone;  

 
(c) 3-p-methoxyphenyl-5-[(4-p-chlorophenoxy-piperidino)methyl]-2-oxazolidinone; 
(d) 3-p-methoxyphenyl-5-[(4-p-hydroxyphenoxy-piperidino)methyl]-2-oxazolidinone; 
(e) 3-p-methoxyphenyl-5-[(4-p-nitrophenoxy-piperidino)methyl]-2-oxazolidinone; 
(f) 3-p-methoxyphenyl-5-[(4-p-chlorophenylthio-piperidino)methyl]-2-oxazolidinone; 
(g) 3-p-methoxyphenyl-5-[(4-p-methylphenylthio-piperidino)methyl]-2-oxazolidinone; 
(h) 3-p-methoxyphenyl-5-[(4-p-methoxyphenylsulfonylpiperidino)methyl]-2-oxazolidinone. 
 
according to Claim 1. 
Process for the preparation of compounds of the 
formula I according to Claim 1 and of the salts thereof, 

characterized in that a compound of the formula II 

 
in which 


R
1
 and m
have the meanings stated in Claim 1 and 
Z
1
is Z or NH
2
, 
Z
is Cl, Br, I, OH, SO
3
CH
3
 or another reactive 
functionally modified OH group, 
 
if Z
1
 = Z,
 
is reacted with a compound of the formula III 


 
in which 


R
2
 and X
have the meanings stated in Claim 1, 
 
or, if Z
1
 = NH
2
,
 
with a compound of the formula IIIa  

 

 
in which 


R
2
and X have the meanings stated in Claim 1 and 
Z
2
 and Z
3
are identical or different and each is Cl, Br, 
I, OH, SO
3
CH
3
 or another reactive functionally 
modified OH group, 
 
or in that a compound which otherwise corresponds to the 

formula I but, in place of one or more hydrogen atoms, 
contains one or more reducible groups and/or one or more 

additional -SO
2
- and/or -SO- groups is treated with a 
reducing agent,
 
or in that to prepare a compound of the formula I 

according to Claim 1 a radical R
1
 and/or R
2
 is converted 
into another radical R
1
 and/or R
2
,
 
or in that a compound of the formula IV 


 
in which R
1
, R
2
, X and m have the stated meanings, is 
reacted with a suitable reactive carbonic acid derivative,
 
or in that a compound of the formula V 


 
in which 


R
1
 and m
have the stated meanings and 
L
is Cl, Br or another suitable leaving group, 
 
is reacted with a compound of the formula VI 


X
1
-R
2
 
in which 


R
2
has the stated meaning and  
 
X
1
is OH, SO
2
H, SH or a suitable salt-like radical 
derivable therefrom, 
 
and/or in that, where appropriate, a compound of the 

formula I is liberated from one of its functional 
derivatives by treatment with a solvolysing or 

hydrolysing agent, or a compound of the formula I is 
converted by reduction or oxidation into another compound 

of the formula I,
 
and/or in that a base of the formula I according to Claim 

1 is converted by treatment with an acid into one of its 
salts. 
Process for the production of pharmaceutical 
preparations, characterized in that a compound of the 

formula I according to Claim 1 and/or one of its physiologically 
acceptable salts is converted together with at 

least one solid, liquid or semiliquid vehicle or ancillary 
substance into a suitable dosage form. 
Pharmaceutical preparation characterized by a 
content of at least one compound of the formula I according 

to Claim 1 and/or one of its physiologically acceptable 
salts. 
Compounds of the formula I according to Claim 1 
and/or their physiologically acceptable salts for controlling 

diseases. 
Use of compounds of the formula I according to 
Claim 1 and/or their physiologi
cally acceptable salts for 
controlling diseases. 
Use of compounds of the formula I according to 
Claim 1 and/or their physiologically acceptable salts for 

the production of medicaments. 
Use of compounds of the formula I according to 
Claim 1 and/or their physiologically acceptable salts for 

the production of neuroleptics. 
</CLAIMS>
</TEXT>
</DOC>
